GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OrbusNeich Medical Group Holdings Ltd (HKSE:06929) » Definitions » ROE %

OrbusNeich Medical Group Holdings (HKSE:06929) ROE % : 10.16% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is OrbusNeich Medical Group Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. OrbusNeich Medical Group Holdings's annualized net income for the quarter that ended in Jun. 2024 was HK$294 Mil. OrbusNeich Medical Group Holdings's average Total Stockholders Equity over the quarter that ended in Jun. 2024 was HK$2,894 Mil. Therefore, OrbusNeich Medical Group Holdings's annualized ROE % for the quarter that ended in Jun. 2024 was 10.16%.

The historical rank and industry rank for OrbusNeich Medical Group Holdings's ROE % or its related term are showing as below:

HKSE:06929' s ROE % Range Over the Past 10 Years
Min: -4.08   Med: 13.07   Max: Negative Equity
Current: 10.67

During the past 5 years, OrbusNeich Medical Group Holdings's highest ROE % was Negative Equity%. The lowest was -4.08%. And the median was 13.07%.

HKSE:06929's ROE % is ranked better than
78.8% of 802 companies
in the Medical Devices & Instruments industry
Industry Median: -0.21 vs HKSE:06929: 10.67

OrbusNeich Medical Group Holdings ROE % Historical Data

The historical data trend for OrbusNeich Medical Group Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OrbusNeich Medical Group Holdings ROE % Chart

OrbusNeich Medical Group Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Negative Equity Negative Equity -4.08 7.31 13.07

OrbusNeich Medical Group Holdings Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROE % Get a 7-Day Free Trial Premium Member Only 7.40 7.24 15.10 11.11 10.16

Competitive Comparison of OrbusNeich Medical Group Holdings's ROE %

For the Medical Instruments & Supplies subindustry, OrbusNeich Medical Group Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OrbusNeich Medical Group Holdings's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OrbusNeich Medical Group Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where OrbusNeich Medical Group Holdings's ROE % falls into.



OrbusNeich Medical Group Holdings ROE % Calculation

OrbusNeich Medical Group Holdings's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=352.011/( (2511.305+2877.13)/ 2 )
=352.011/2694.2175
=13.07 %

OrbusNeich Medical Group Holdings's annualized ROE % for the quarter that ended in Jun. 2024 is calculated as

ROE %=Net Income (Q: Jun. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Jun. 2024 ))/ count )
=294.094/( (2877.13+2911.302)/ 2 )
=294.094/2894.216
=10.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2024) net income data. ROE % is displayed in the 30-year financial page.


OrbusNeich Medical Group Holdings  (HKSE:06929) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=294.094/2894.216
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(294.094 / 1232.574)*(1232.574 / 3223.845)*(3223.845 / 2894.216)
=Net Margin %*Asset Turnover*Equity Multiplier
=23.86 %*0.3823*1.1139
=ROA %*Equity Multiplier
=9.12 %*1.1139
=10.16 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=294.094/2894.216
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (294.094 / 332.472) * (332.472 / 267.634) * (267.634 / 1232.574) * (1232.574 / 3223.845) * (3223.845 / 2894.216)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8846 * 1.2423 * 21.71 % * 0.3823 * 1.1139
=10.16 %

Note: The net income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


OrbusNeich Medical Group Holdings ROE % Related Terms

Thank you for viewing the detailed overview of OrbusNeich Medical Group Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


OrbusNeich Medical Group Holdings Business Description

Traded in Other Exchanges
Address
3rd Floor, Building 20E, Units 303 and 305, Hong Kong Science Park, Shatin New Town, Hong Kong, HKG
OrbusNeich is a China-based global medical device maker of endovascular interventional instruments with global reach. It launched its first research base in 2001 and was listed on the Hong Kong Exchange in 2022. As of 2023, OrbusNeich's largest revenue segment by geography is Japan with 24.7% of total revenue followed by Europe, the Middle East, and Africa, with 23.6% of total revenue. The Asia-Pacific region and the United States make up the balance. Its largest product segment is coronary interventional medical devices, such as scoring balloons, non-compliant balloons, or stents, together representing 82.7% of its total revenue.
Executives
Harmony Tree Limited 2101 Beneficial owner
Shenzhen Capital Group Co., Ltd. 2201 Interest of corporation controlled by you
Suzhou Red Earth Yeju Investment Ltd. 2101 Beneficial owner
Chien David 2201 Interest of corporation controlled by you
Lau Kwai Ching Denise 2201 Interest of corporation controlled by you
Shen Chuang Tou Zhi Zao Ye Zhuan Xing Sheng Ji Xin Cai Liao Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you
Shen Chuang Tou Hong Tu Si Mu Gu Quan Tou Zi Ji Jin Guan Li Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Hong Tu Ye Ju Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you

OrbusNeich Medical Group Holdings Headlines

No Headlines